Company Overview of Ardelyx, Inc.
Ardelyx, Inc. discovers, develops, and commercializes minimally-systemic therapeutics for the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. Its lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with constipation-predominant irritable bowel syndrome, as well as in Phase IIb clinical trial for the treatment of hyperphosphatemia or elevated serum phosphorus levels in patients with end-stage renal disease. The company is also developing RDX022, an oral, non-absorbed potassium-binder for the treatment of hyperkalemia or elevated serum potassium. Its drug candidates in earlier stages of research and development include RDX0...
34175 Ardenwood Boulevard
Fremont, CA 94555
Founded in 2007
Key Executives for Ardelyx, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $470.0K
Chief Financial Officer and Principal Accounting Officer
Total Annual Compensation: $320.0K
Senior Vice President and General Counsel
Total Annual Compensation: $300.0K
Chief Scientific Officer and Executive Vice President
Total Annual Compensation: $132.1K
Compensation as of Fiscal Year 2015.
Ardelyx, Inc. Key Developments
Ardelyx, Inc. - Special Call
Jun 22 16
To provide update regarding its ongoing Phase 2b clinical trial evaluating tenapanor for the treatment of hyperphosphatemia for end-stage renal disease (ESRD) patients on dialysis
Ardelyx, Inc. Presents at JMP Securities 2016 Life Sciences Conference, Jun-22-2016 10:30 AM
Jun 9 16
Ardelyx, Inc. Presents at JMP Securities 2016 Life Sciences Conference, Jun-22-2016 10:30 AM. Venue: The St. Regis New York, 2 East 55th Street, New York, NY 10022, United States.
Ardelyx, Inc. Appoints Robert Bazemore as Member of its Board of Directors and Member of the Compensation Committee of the Board
Jun 7 16
On June 2, 2016, Ardelyx, Inc. appointed Robert Bazemore, effective immediately, to serve in Class III until the 2017 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal. In connection with Mr. Bazemore's appointment, the Board increased the authorized number of members of the Board from six to seven members. Following Mr. Bazemore's appointment, Class III consists of Gordon Ringold, Ph.D., Richard Rodgers, and Mr. Bazemore. Mr. Bazemore was also appointed to serve as a member of the Compensation Committee of the Board (the Compensation Committee). Following Mr. Bazemore's appointment, the Compensation Committee consists of David Mott, as chairman, Dr. Ringold, Mr. Rodgers, and Mr. Bazemore.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 15, 2016